"The U.S.-China Economic and Security Review Commission is watching the events now unfolding in Hong Kong with great concern. We support an open and democratic system in Hong Kong based on universal suffrage, freedom of expression, and freedom of assembly. As called for in the Basic Law, Hong Kong should have a high degree of autonomy, which is essential to maintaining its long-term stability and prosperity. To do so, we urge Hong Kong’s leadership to adopt an election process based on universal suffrage which provides a genuine choice of candidates representing the true aspirations of the Hong Kong people. Hong Kong’s traditions of openness and freedom are well-established. We urge Hong Kong and Chinese authorities to exercise restraint and to respect protestors’ right to continue to express their views on Hong Kong's future in a peaceful manner." On November 19, the Commission will publicly release its annual report, which will include recommendations to Congress on Hong Kong.

The hearing will examine economic, political, and security developments in cross-Strait and China-North Korea relations. It will assess the opportunities and risks arising from closer cross-Strait economic integration for Taiwan and the United States, and it will examine Taiwan’s ability to defend against military coercion by China. The hearing will also address whether China’s views and policies toward North Korea have changed in recent years and the implications for U.S. security interests.

This hearing will examine, among other things, China’s energy needs and clean energy policies, the recent developments in the U.S.-China clean energy cooperation, and the implications of such cooperation for the United States.

This hearing will address China’s recent healthcare reforms, market access for U.S. medical goods and services in China, and the safety of medical products imported from China into the United States. China is growing more affluent and urbanized, and is also facing new healthcare challenges. The Chinese government has launched ambitious reforms to expand coverage and improve care. This hearing will consider whether U.S. drug and medical device makers are able to compete in China’s market. It will also assess the U.S. Food and Drug Administration’s ongoing efforts to regulate drugs and drug ingredients imported from China into the United States.